Relay Therapeutics (RLAY)
(Delayed Data from NSDQ)
$7.50 USD
-0.36 (-4.58%)
Updated Sep 20, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Relay Therapeutics, Inc. [RLAY]
Reports for Purchase
Showing records 1 - 20 ( 26 total )
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
SHP2 Collaboration With Roche Terminated; Lowering PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
Three New Programs Revealed; Clinical Trial Agreement Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
PIK3CA-Mutated Breast Cancer Competitive Landscape Updates; Modulating PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
Lirafugratinib Shows Promise For Tumor Agnostic Use; Regulatory Strategy Revised; Raising PT to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
Updated RLY-2608 Data Released; 2Q23 Financials; Modulating PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
Updated Results For RLY-4008 at ASCO; Landscape Updates; 1Q23 Financials; Lowering PT to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
Initial RLY-2608 Data at AACR; 2022 Financials; Modulating PT to $46
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
RLY-4008 Likely to Become the Go-To FGFR2i in CCA, in our View; Raising PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
Updated RLY-4008 Results in 2H22; 2Q22 Financials; Modulating PT to $46
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
Updated RLY-4008 Results; Three New Programs Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
Full-Year 2021 Financials Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
RLY-4008 Demonstrates Encouraging Efficacy and Safety; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
Company: Relay Therapeutics, Inc.
Industry: Medical - Drugs
Collaboration Agreement With EQRx Inked; 2Q21 Financials; Lowering PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R